<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306017</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8258</org_study_id>
    <secondary_id>2016-A01601-50</secondary_id>
    <nct_id>NCT03306017</nct_id>
  </id_info>
  <brief_title>Effects of Left Ventricular Assist Device Implantation on the Phenotype of Blood Platelets and Leucocytes</brief_title>
  <acronym>DAV-HÃ©mo</acronym>
  <official_title>Study on the Effects of Left Ventricular Assist Device Implantation on the Phenotype of Blood Platelets and Leucocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare in vivo platelet and leukocyte activation and phenotype before and after Left
      ventricular assist device (LAVD) implantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study plan to investigate platelet activation in vivo using a variety of
      biomarkers previously identified as sensitive to high shear stress in patients with severe
      aortic valve stenosis before and after trans arterial valve replacement. As one of the best
      biomarker is a high degree of platelet-leukocyte interactions, the study will study in
      parallel leukocytes activation/differentiation. These parameters will be compared at 3
      time-points, before and after LAVD implantation in ambulatory patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet activation</measure>
    <time_frame>Month 2 after LAVD implantation</time_frame>
    <description>To compare platelet activation in vivo, using a composite criteria determinated by variety of biomarkers of activation analysed by flow cytometry and enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of circulating platelet-leukocyte conjugate</measure>
    <time_frame>Month 2 after LAVD implantation</time_frame>
    <description>To determine the level of circulating platelet-leukocyte conjugate by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in leukocyte phenotype</measure>
    <time_frame>Month 2 after LAVD implantation</time_frame>
    <description>To determine the leukocyte phenotype which is a composite criteria analysed by flow cytometry, ELISA and lipidaemic analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cardiac Insufficiency</condition>
  <arm_group>
    <arm_group_label>LAVD implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten patients before and after LAVD implantation had blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.</description>
    <arm_group_label>LAVD implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective implantation of LAVD (Heartmate II),

          -  written informed consent to the study

          -  Patients with health insurance

        Exclusion Criteria:

          -  treatment or procedure that could affect platelet functions or turn-over(low-dose
             aspirin is allowed).

          -  Pregnancy or breastfeeding

          -  Juridical Protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre SIE, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Toulouse, Rangueil, Hematology laboratory</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre SIE, MD, PhD</last_name>
    <phone>05 61 32 22 89</phone>
    <email>sie.p@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre SIE</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>left ventricular assist device</keyword>
  <keyword>platelet-leukocyte conjugates</keyword>
  <keyword>lipo-oxygenase products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

